SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: BulbaMan who wrote (11859)6/1/2004 2:06:58 PM
From: Biomaven  Read Replies (1) | Respond to of 52153
 
<POZN>

Certainly the triptan/nsaid combo that they licensed to GSK has no particular safety concerns. The only question is whether they will be able to satisfy the FDA on the combination product standard - that the combo is demonstrably superior to both constituents. My feeling is that they will, although the FDA seems somewhat fixated on the 2 hour time period where the combo may not easily demonstrate superiority.

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News